Nicotinamide Phosphoribosyltransferase Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12 Pipeline Review, H2 2018
Summary
Nicotinamide Phosphoribosyltransferase Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12 pipeline Target constitutes close to 11 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report Nicotinamide Phosphoribosyltransferase Pipeline Review, H2 2018, outlays comprehensive information on the Nicotinamide Phosphoribosyltransferase Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.
Nicotinamide Phosphoribosyltransferase Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12 Nicotinamide phosphoribosyltransferase NAmPRTase is an enzyme encoded by the PBEF1 gene. This protein has also been reported to be a cytokine PBEF that promotes B cell maturation and inhibits neutrophil apoptosis. NAmPRTase catalyzes the condensation of nicotinamide with 5phosphoribosyl1pyrophosphate to yield nicotinamide mononucleotide, one step in the biosynthesis of nicotinamide adenine dinucleotide. The protein is an adipokine that is localized to the bloodstream and has various functions, including the promotion of vascular smooth muscle cell maturation and inhibition of neutrophil apoptosis. It also activates insulin receptor and has insulinmimetic effects, lowering blood glucose and improving insulin sensitivity.
The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 8 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Immunology and Respiratory which include indications Acute Lymphocytic Leukemia ALL, Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia, Age Related Memory Impairment, Amyotrophic Lateral Sclerosis, Depression, Lymphoma, Multiple Myeloma Kahler Disease, Parkinson's Disease, Acute Lung Injury, Breast Cancer, Colon Cancer, Idiopathic Pulmonary Fibrosis, Inflammation, Leukemias, Lung Cancer, Nerve Injury, Neuroendocrine Tumors, NonHodgkin Lymphoma, Pain, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pulmonary Arterial Hypertension, Renal Cell Carcinoma, Sarcomas, Solid Tumor and Waldenstrom Macroglobulinemia Lymphoplasmacytic Lymphoma.
Furthermore, this report also reviews key players involved in Nicotinamide Phosphoribosyltransferase Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for Nicotinamide Phosphoribosyltransferase Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12
The report reviews Nicotinamide Phosphoribosyltransferase Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Nicotinamide Phosphoribosyltransferase Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12 targeted therapeutics and enlists all their major and minor projects
The report assesses Nicotinamide Phosphoribosyltransferase Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Nicotinamide Phosphoribosyltransferase Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Nicotinamide Phosphoribosyltransferase Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Nicotinamide Phosphoribosyltransferase Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope